Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Todd Neale

September 21, 2022

Presentation TCT 2022

Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures: The RIVARAD Multicentric Randomized Trial

Presenter: Rania Hammami

September 19, 2022

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2013

Case Presentation: A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2012

Should Rivaroxaban Be Used in STEMI Patients, and Does Choice of ADP Antagonist (with Rivaroxaban) Matter?

Presenter: C. Michael Gibson

October 25, 2012

Presentation TCT 2012

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Presenter: Harvey White

October 22, 2012

Advertisement

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures: The RIVARAD Multicentric Randomized Trial

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Case Presentation: A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI

Should Rivaroxaban Be Used in STEMI Patients, and Does Choice of ADP Antagonist (with Rivaroxaban) Matter?

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content